company background image
NXTC

NextCure NasdaqGS:NXTC Stock Report

Last Price

US$1.66

Market Cap

US$46.1m

7D

-0.6%

1Y

-68.9%

Updated

05 Feb, 2023

Data

Company Financials +

NXTC Stock Overview

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function.

NXTC fundamental analysis
Snowflake Score
Valuation2/6
Future Growth0/6
Past Performance0/6
Financial Health6/6
Dividends0/6

My Notes

New

Notes are coming soon

NextCure, Inc. Competitors

Price History & Performance

Summary of all time highs, changes and price drops for NextCure
Historical stock prices
Current Share PriceUS$1.66
52 Week HighUS$5.54
52 Week LowUS$1.16
Beta-0.023
1 Month Change2.47%
3 Month Change-2.92%
1 Year Change-68.91%
3 Year Change-96.33%
5 Year Changen/a
Change since IPO-91.66%

Recent News & Updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Nov 22
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Recent updates

We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Nov 22
We're Keeping An Eye On NextCure's (NASDAQ:NXTC) Cash Burn Rate

Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

Aug 09
Estimating The Intrinsic Value Of NextCure, Inc. (NASDAQ:NXTC)

NextCure GAAP EPS of -$0.59

Aug 04

We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

May 02
We're Not Very Worried About NextCure's (NASDAQ:NXTC) Cash Burn Rate

NextCure: Large Upside With Downside Protected By Cash Pile

Sep 29

NextCure (NXTC) Presents at 7th Annual Truist Securities Life Sciences Summit - Slideshow

May 10

NextCure EPS misses by $0.01

May 06

Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

Feb 12
Here's What NextCure, Inc.'s (NASDAQ:NXTC) Shareholder Ownership Structure Looks Like

NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

Jan 08
NextCure's (NASDAQ:NXTC) Shareholders Are Down 80% On Their Shares

NextCure provides update on NC318 clinical program

Dec 17

Shareholder Returns

NXTCUS BiotechsUS Market
7D-0.6%-0.8%1.7%
1Y-68.9%4.3%-9.6%

Return vs Industry: NXTC underperformed the US Biotechs industry which returned 4.4% over the past year.

Return vs Market: NXTC underperformed the US Market which returned -9.6% over the past year.

Price Volatility

Is NXTC's price volatile compared to industry and market?
NXTC volatility
NXTC Average Weekly Movement10.0%
Biotechs Industry Average Movement12.1%
Market Average Movement6.7%
10% most volatile stocks in US Market17.5%
10% least volatile stocks in US Market2.8%

Stable Share Price: NXTC is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 10% a week.

Volatility Over Time: NXTC's weekly volatility (10%) has been stable over the past year.

About the Company

FoundedEmployeesCEOWebsite
201587Michael Richmanhttps://www.nextcure.com

NextCure, Inc., a clinical-stage biopharmaceutical company, engages in discovering and developing novel immunomedicines to treat cancer and other immune-related diseases by restoring normal immune function. Its lead product candidate is NC318, which is in Phase II clinical trials for the treatment of advanced or metastatic solid tumors. The company is also developing NC410, which is in Phase I for novel immunomedicine designed to block immune suppression mediated by an immune modulator called Leukocyte-Associated Immunoglobulin-like Receptor 1; NC762, an immunomedicine targeting a molecule called human B7 homolog 4 protein, or B7-H4; and NC525, a novel LAIR-1 antibody which is in Preclinical trails that targets acute myeloid leukemia, blast cells, and leukemic stem cells.

NextCure, Inc. Fundamentals Summary

How do NextCure's earnings and revenue compare to its market cap?
NXTC fundamental statistics
Market CapUS$46.11m
Earnings (TTM)-US$74.37m
Revenue (TTM)n/a

0.0x

P/S Ratio

-0.6x

P/E Ratio

Earnings & Revenue

Key profitability statistics from the latest earnings report
NXTC income statement (TTM)
RevenueUS$0
Cost of RevenueUS$4.08m
Gross Profit-US$4.08m
Other ExpensesUS$70.29m
Earnings-US$74.37m

Last Reported Earnings

Sep 30, 2022

Next Earnings Date

n/a

Earnings per share (EPS)-2.68
Gross Margin0.00%
Net Profit Margin0.00%
Debt/Equity Ratio0%

How did NXTC perform over the long term?

See historical performance and comparison